Descrição

The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 bilhão durante 2021-2027, crescendo a uma taxa composta de crescimento anual (CAGR) de 27% durante o período de previsão, de acordo com a empresa de dados e análise StrategyHelix.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2017-2020 e previsão para 2027 covering key market aspects like sales value for autoimmune diseases treatment. The China autoimmune diseases treatment market is segmented on the basis of product, type. Por produto, it is categorized into biologics, and small molecule chemical drugs. The small molecule chemical drugs segment held the largest market share in 2020. No entanto, the biologics segment is expected to witness the highest CAGR during the forecast period. Por tipo, the autoimmune diseases treatment market is divided into immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE).

The report has profiled some of the key players of the market such as UCB S.A., AbbVie Inc., GlaxoSmithKline plc., Janssen Pharmaceutica NV, Novartis International AG, Pfizer Inc., Roche Holding AG, Rongchang Pharmacy Co. Ltda..

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

produtos: biologics, and small molecule chemical drugs
Tipo: immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE)
Anos considerados: este relatório cobre o período 2017 para 2027

Principais benefícios para as partes interessadas

Get a comprehensive picture of the China autoimmune diseases treatment market
Identifique setores de crescimento e tendências para investimento
Understand what the future of the autoimmune diseases treatment market in China looks like
Identifique o cenário competitivo e a janela de oportunidade

Índice

1. Definição de mercado
2. Metodologia de Pesquisa
3. Dados de mercado & Panorama
3.1 Valor de mercado
3.2 Previsão de valor de mercado
4. Autoimmune Diseases Treatment Market by Product
4.1 Biologics
4.2 Small Molecule Chemical Drugs
5. Autoimmune Diseases Treatment Market by Type
5.1 Immunoglobulin A Nephropathy (IgAN)
5.2 Multiple Sclerosis (MS)
5.3 Myasthenia Gravis (MG)
5.4 Neuromyelitis Optica Spectrum Disorder (NMOSD)
5.5 Rheumatoid Arthritis (RA)
5.6 Sjogren’S Syndrome (SS)
5.7 Systemic Lupus Erythematosus (SLE)
6. Perfis de empresa
6.1 UCB S.A.
6.2 AbbVie Inc.
6.3 GlaxoSmithKline plc.
6.4 Janssen Pharmaceutica NV
6.5 Novartis International AG
6.6 Pfizer, Inc..
6.7 Roche Holding AG
6.8 Rongchang Pharmacy Co., Ltda.
7. Apêndice
7.1 Sobre StrategyHelix
7.2 Isenção de responsabilidade